Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of CytoDyn Inc. from 31 May 2016 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
CytoDyn Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 May 2016 to 30 Nov 2025.
  • CytoDyn Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Nov 2025 was $4,982,000, a 77% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

CytoDyn Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,982,000 -$16,353,000 -77% 30 Nov 2025 10-Q 09 Jan 2026 2026 Q2
Q3 2025 $9,332,000 -$15,589,000 -63% 31 Aug 2025 10-Q 10 Oct 2025 2026 Q1
Q2 2025 $11,903,000 +$2,089,000 +21% 31 May 2025 10-Q 09 Jan 2026 2026 Q2
Q1 2025 $16,400,000 +$8,377,000 +104% 28 Feb 2025 10-Q 14 Apr 2025 2025 Q3
Q4 2024 $21,335,000 +$14,611,000 +217% 30 Nov 2024 10-Q 09 Jan 2026 2026 Q2
Q3 2024 $24,921,000 +$16,349,000 +191% 31 Aug 2024 10-Q 10 Oct 2025 2026 Q1
Q2 2024 $9,814,000 +$766,000 +8.5% 31 May 2024 10-Q 09 Jan 2026 2026 Q2
Q1 2024 $8,023,000 -$3,087,000 -28% 29 Feb 2024 10-Q 14 Apr 2025 2025 Q3
Q4 2023 $6,724,000 +$4,121,000 +158% 30 Nov 2023 10-Q 14 Jan 2025 2025 Q2
Q3 2023 $8,572,000 +$3,896,000 +83% 31 Aug 2023 10-Q 15 Oct 2024 2025 Q1
Q2 2023 $9,048,000 +$4,817,000 +114% 31 May 2023 10-K 25 Jul 2025 2025 FY
Q1 2023 $11,110,000 +$8,747,000 +370% 28 Feb 2023 10-Q 15 Apr 2024 2024 Q3
Q4 2022 $2,603,000 -$6,272,000 -71% 30 Nov 2022 10-Q 16 Jan 2024 2024 Q2
Q3 2022 $4,676,000 -$1,866,000 -29% 31 Aug 2022 10-Q 23 Oct 2023 2024 Q1
Q2 2022 $4,231,000 -$29,712,000 -88% 31 May 2022 10-K 15 Aug 2024 2024 FY
Q1 2022 $2,363,000 -$11,928,000 -83% 28 Feb 2022 10-Q 10 Apr 2023 2023 Q3
Q4 2021 $8,875,000 -$20,532,000 -70% 30 Nov 2021 10-Q 09 Jan 2023 2023 Q2
Q3 2021 $6,542,000 -$11,671,000 -64% 31 Aug 2021 10-Q/A 13 Oct 2022 2023 Q1
Q2 2021 $33,943,000 +$19,651,000 +137% 31 May 2021 10-K 14 Sep 2023 2023 FY
Q1 2021 $14,291,000 +$7,234,000 +103% 28 Feb 2021 10-Q 11 Apr 2022 2021 Q3
Q4 2020 $29,407,000 +$28,207,000 +2351% 30 Nov 2020 10-Q 10 Jan 2022 2021 Q2
Q3 2020 $18,213,000 +$16,417,000 +914% 31 Aug 2020 10-Q 12 Oct 2021 2021 Q1
Q2 2020 $14,292,000 +$10,825,000 +312% 31 May 2020 10-K 15 Aug 2022 2022 FY
Q1 2020 $7,057,000 +$5,463,371 +343% 29 Feb 2020 10-Q 14 Apr 2021 2020 Q3
Q4 2019 $1,200,000 +$427,639 +55% 30 Nov 2019 10-Q 08 Jan 2021 2020 Q2
Q3 2019 $1,796,000 -$2,953,413 -62% 31 Aug 2019 10-Q 09 Oct 2020 2020 Q1
Q2 2019 $3,467,000 +$2,236,000 +182% 31 May 2019 10-K 15 Aug 2022 2022 FY
Q1 2019 $1,593,629 28 Feb 2019 10-Q 09 Apr 2020 2020 Q3
Q4 2018 $772,361 30 Nov 2018 10-Q 09 Jan 2020 2020 Q2
Q3 2018 $4,749,413 31 Aug 2018 10-Q 08 Oct 2019 2020 Q1
Q2 2018 $1,231,000 -$544,583 -31% 31 May 2018 10-K 30 Jul 2021 2021 FY
Q2 2017 $1,775,583 -$7,866,193 -82% 31 May 2017 10-K 14 Aug 2020 2020 FY
Q2 2016 $9,641,776 31 May 2016 10-K 14 Aug 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.